mortality rates. COVID-19 pandemic has served as a model that highlights the importance of universal and streamlined healthcare access.

Conflict of interest
Dr Koch received grants from Novartis and honoraria as speaker and travel fees from Novartis, Bristol Myers Squibb, Roche and Merck & Co. Dr Mondaca has received consulting fees from Roche and Foundation Medicine and honoraria as speaker from Bristol Myers Squibb and Merck & Co.

Funding sources
Dr Marchetti’s research is funded in part through the Memorial Sloan Kettering Cancer Center Institutional National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.

E. Koch,1,2 F. Villanueva,1,2 M.A. Marchetti,3 Á. Abarzúa-Araya,4 C. Cárdenas,4 J.C. Castro,4 F. Dominguez,5 K. Droppelmann,4 N. Droppelmann,6 H. Galindo,1,2 A. León,2,5 J. Madrid,1,5 M. Molgó,2,4 S. Mondaca,1,2 P.H. Montero,2,5 P. Uribe,2,4 M.A. Villaseca,2,7,8 E. Vinés,2,9 C. Navarrete-Dechent2,4,*
1Department of Hematology and Oncology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 2Melanoma and Skin Cancer Unit, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 3Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 5Department of Surgical Oncology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 6Department of Surgery, Clínica Universidad de Los Andes, Santiago, Chile, 7Department of Pathology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 8Department of Pathology, Universidad de la Frontera, Temuco, Chile, 9Department of Radiation Oncology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

*Correspondence: C. Navarrete-Dechent. E-mail: ctnavarr@gmail.com

Erica Koch and Francisco Villanueva Shared first authorship.

References
1 Breitbart EW, Waldmann A, Nolte S et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66: 201–211.
2 Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–6206.
3 Marson JW, Maner BS, Harding TP et al. The magnitude of COVID-19’s effect on the timely management of melanoma and nonmelanoma skin cancers. J Am Acad Dermatol 2021; 84: 1100–1103.
4 Lallas A, Kyrgidis A, Manoli SM et al. Delayed skin cancer diagnosis in 2020 because of the COVID-19-related restrictions: data from an institutional registry. J Am Acad Dermatol 2021. In press. https://doi.org/10.1016/j.jaad.2021.05.021
5 Tejera-Vaquero A, Nagore E. Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model. J Eur Acad Dermatol Venereol 2020; 34: e351–e353.

A skin reaction with rust-like discoloration to mRNA COVID-19 vaccine

Editor
We describe a reaction that occurred in three cases after the BNT162b2 mRNA COVID-19 vaccine (Comirnaty®; BioNTech, Mainz, Germany and Pfizer, New York City, NY, USA). All cases were female, two of them aged 50 and one 51 years. All subjects had experienced a similar reaction after vaccination; part of their skin turned a brownish, rust-like colour. The respective locations of these reactions were (i) the left palmar area and right arm (Fig. 1), (ii) the dorsal surface of the left hand and (iii) the right palm and fingers (Fig. 2).

Two of these reactions occurred after the first vaccination and one after the booster. In the case of the booster, the reaction was observed approximately one and a half hours after the vaccination. In those subjects receiving only one vaccination, the reactions appeared the following night and after 5 days, respectively. All subjects are healthcare workers working with elderly people, and thus among the first to be vaccinated in Finland. All three had been previously vaccinated according to the Finnish national vaccination programme. They had also received the annual influenza vaccine.

Figure 1 Reaction in left palm.
required for healthcare workers. Two of these individuals had a known IgE-mediated allergy to pollen, and one of them also had a contact allergy to nickel. Those with a history of IgE allergy had taken paracetamol (acetaminophen) prior to vaccination, and the other one had also taken cetirizine an hour before. All the reactions subsided in 24 h, due to which no biopsy specimen could, for practical reasons, be taken. All three had pain at the vaccination site for two days as another adverse event; two out of three also experienced some flu-like symptoms the following day.

We have no idea of the possible mechanism for the phenomena, but, interestingly, all patients were of the same age. Pollen allergy is very common in Finland, and the relevance of the atopic diathesis remains unclear. A delayed reaction to another mRNA-based vaccine (mRNA-1273) has been reported,1 but the reactions described are of a classic inflammatory nature. A similar reaction has also been reported for the BNT162b2 vaccine.2,3 In a registry-based study with 414 reported cases with cutaneous reaction, altogether four cases of petechiae were reported4 but not described in more detail.

The reaction we now describe would suggest a haemosiderin pigmentation, but vanishes too rapidly to be explained as such. We suspect that this reaction is a local capillary leakage due to the vaccination and some kind of immunologic reaction located in the dermis/epidermis junction.

Acknowledgements
The patients in this manuscript have given written informed consent to the publication of their case details.

Conflict of interest
We have no conflict of interest to disclose concerning this work.

Funding sources
We received no funding to support for this work.

R. Pasternack,1,* S. Pohjavaara2
1Department of Dermatology, Tampere University Hospital and Tampere University, Tampere, Finland, 2Pirkkala Health Care Centre, Pirkkala, Finland
*Correspondence: R. Pasternack. E-mail: rafael.pasternack@pshp.fi

References
1 Blumenthal KG, Freeman EE, Saff RR et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med 2021; 384: 1273–1277.
2 Baeck M, Marot L, Belkhir L. Delayed large local reactions to mRNA vaccines. N Engl J Med 2021; 384: 1056.
3 Fernandez-Nieto D, Hammerle J, Fernandez-Escribano M et al. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. ’COVID-arm’: a clinical and histological characterization. J Eur Acad Dermatol Venereol 2021; 35: e425–e427.
4 McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46–55.

DOI: 10.1111/jdv.17543

Dermatoses caused by face mask wearing during the COVID-19 pandemic

Editor
We present 6 patients with different dermatoses caused by face mask wearing during the COVID-19 pandemic. Physical examination revealed lesions only under masks.

Two 20 years old females presented to our clinic with the pustules and papules on the face area. Due to the COVID-19 pandemic, the patients began to use neoprene mask with daily change. The first papules and pustules appeared in the mask area about two weeks of mask using. The diagnosis of mask induced acne (‘maskne’) was made (Fig. 1a–c).

Two 25 and 23 years old patients presented with irregular pink-yellow patches with sharp borders and small serous crusts. No concomitant disorders, professional harm and bad habits

Figure 2 Reaction in right palm.